Liquid-Liquid Extraction Assisted Reverse phase HPLC Method for Quantitative Estimation of Dapagliflozin from Biological Matrix-Human Plasma: Development and Validation
Keywords:
Antidiabetic, Bioanalytical method development, Dapagliflozin, Liquid-liquid extraction, Reverse Phase High Performance Liquid ChromatographyAbstract
High performance liquid chromatography (HPLC) method was developed and validated for determination of Dapagliflozin in spiked human plasma using ornidazole as an internal standard (IS) for therapeutic monitoring. The resolution was achieved on Hemsil C18 column with mobile phase composed of Methanol : Double distilled water (80 : 20%) at flow rate 1ml/min. and detection wavelength was 236 nm. Sample preparation was carried out to separate Dapagliflozin from biological matrices by liquid-liquid extraction method. The developed method could give resolved peak of Dapagliflozin and Ornidazole at 5.2 and 3.2 min. respectively. The method was validated as per ICH M10 guidelines. The method was linear in range of 10 to 50 µg/ ml and it’s lower limit of quantitation and limit of quantitation were 10-50 µg/ ml respectively. The intra- and inter-day precision (%CV) were found to be in range of 0.77 to 7.20%, its accuracies were > 96% and recovery studies in range of 76.14 to 89.12%. Results of stability studies were found to be within specified range. The proposed method is characterized with highly sensitive, accurate, rapidity, as it consumes low volume of organic solvent in mobile phase and has high analysis throughput as its run time was short (~10 min).
Downloads
Metrics
References
Mante G, Hemke A, Umekar M. RP-HPLC method for estimation of Dapagliflozin from its tablet. Int. J. ChemTech Res. 2018;11(01):242-248.
Urooj A, Sundar P, Vasanthi R et al. Development and validation of RP-HPLC method for simultaneous estimation of Dapagliflozin and metformin in bulk and in synthetic mixture. World J Pharm Pharm Sci. 2017;6(7):2139-2150.
Manoharan G, Ismaiel A, Ahmed Z. Stability-indicating RP-HPLC method development for simultaneous determination and estimation of Dapagliflozin in raw and tablet formulation. Chem Res J. 2018;3(2):159-164.
Donepudi S, Achanta S. Simultaneous estimation of saxagliptin and Dapagliflozin in human plasma by validated high performance liquid chromatography-ultraviolet method. Turk J Pharm Sci. 2019;16(2):227.
Shah P, Shrivastav P, Shah J, George A. Simultaneous quantitation of metformin and Dapagliflozin in human plasma by LC–MS/MS: Application to a pharmacokinetic study. Biomed. Chromatogr. 2019;33(4):e4453.
El-Zaher A, Hashem H, Elkady E, Allam M. A validated LC-MS/MS bioanalytical method for the simultaneous determination of Dapagliflozin or saxagliptin with metformin in human plasma. Microchem. J. 2019;149:104017.
Dias B, Fachi M, de Campos M, Degaut F, Peccinini R, Pontarolo R. A new HPLC–MS/MS method for the simultaneous quantification of SGLT2 inhibitors and metformin in plasma and its application to a pharmacokinetic study in healthy volunteers. Biomed. Chromatogr. 2019;33(11):e4663.
Habeeb M, Morshedy S, Daabees H, Elonsy S. Whiteness and greenness assessments of a sensitive HPLC method with fluorimetric detection for Dapagliflozin quantitation in human plasma: Application to a healthy human volunteer. Arch. Pharm. 2024;357(10):e2400313.
PubChem [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004-. PubChem Compound Summary for CID 9887712, Dapagliflozin; [cited 2024 Dec. 27].
Vazvaei-Smith F, Wickremsinhe E, Woolf E, Yu C. ICH M10 Bioanalytical Method Validation Guideline-1 year Later. AAPS J. 2024 Sep;26(5):103.
Booth B, Stevenson L, Pillutla R et al. 2019 white paper on recent issues in bioanalysis: FDA BMV guidance, ICH M10 BMV guideline and regulatory inputs (part 2–recommendations on 2018 FDA BMV guidance, 2019 ICH M10 BMV draft guideline and regulatory Agencies' input on bioanalysis, biomarkers and immunogenicity). Bioanalysis. 2019 Dec;11(23):2099-132.
Gniazdowska E, Gilant E, Buś-Kwaśnik K. ICH M10 guideline-a harmonized global approach to bioanalysis. Prospect. Pharm. Sci. 2023;21(3):57-63.
Bode G. Regulatory Guidance: ICH, EMA, FDA. Drug discovery and evaluation. Clin. Pharmacol. 2020:1085-138.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
